key: cord-0715424-b0kx40t2 authors: Koh, Jasmine Shimin; Hoe, Rebecca Hui Min; Yong, Ming Hui; Chiew, Hui Jin; Goh, Yihui; Yong, Kok Pin; Tu, Tian Ming; Chan, Derrick Wei Shih; Tan, Benjamin Yong-Qiang; Yeo, Leonard Leong Litt; Quek, Amy May Lin; Siow, Isabel; Saini, Monica; Angon, Jasmyn; Rathakrishnan, Sharmini; Chen, Geraldine Jiangyan; Hui, Andrew Che-Fai; Ahmad, Aftab; Shwe, Moe Pearl; Tan, Kevin; Seet, Raymond Chee Seong; Cai, Mingshi; Kuo, Si Min; Foo, Ling Li; Umapathi, Thirugnanam title: Hospital-based observational study of neurological disorders in patients recently vaccinated with COVID-19 mRNA vaccines date: 2021-10-13 journal: J Neurol Sci DOI: 10.1016/j.jns.2021.120030 sha: 1b268077d49fa936da47b488ea27d1141d293d20 doc_id: 715424 cord_uid: b0kx40t2 PURPOSE: We describe the spectrum of acute neurological disorders among hospitalized patients who recently had COVID-19 mRNA vaccination. METHOD: We performed a prospective study at 7 acute hospitals in Singapore. Hospitalized patients who were referred for neurological complaints and had COVID-19 mRNA vaccines, BNT162b2 and mRNA-1273, in the last 6 weeks were classified into central nervous system (CNS) syndromes, cerebrovascular disorders, peripheral nervous system (PNS) disorders, autonomic nervous system (ANS) disorders and immunization stress-related responses (ISRR). RESULTS: From 30 December 2020 to 20 April 2021, 1,398,074 persons (median age 59 years, 54.5% males) received COVID-19 mRNA vaccine (86.7% BNT162b2, 13.3% mRNA-1273); 915,344(65.5%) completed 2 doses. Four hundred and fifty-seven(0.03%) patients were referred for neurological complaints [median age 67(20–97) years, 281(61.5%) males; 95.8% received BNT162b2 and 4.2% mRNA-1273], classified into 73(16.0%) CNS syndromes, 286(62.6%) cerebrovascular disorders, 59(12.9%) PNS disorders, 0 ANS disorders and 39(8.5%) ISRRs. Eleven of 27 patients with cranial mononeuropathy had Bell's palsy. Of 33 patients with seizures, only 4 were unprovoked and occurred within 2 weeks of vaccination. All strokes occurred among individuals with pre-existing cardiovascular risk factors. We recorded 2 cases of cerebral venous thrombosis; none were vaccine-induced thrombotic thrombocytopenia. Five had mild flares of immune-mediated diseases. CONCLUSION: Our observational study does not establish causality of the described disorders to vaccines. Though limited by the lack of baseline incidence data of several conditions, we observed no obvious signal of serious neurological morbidity associated with mRNA vaccination. The benefits of COVID-19 vaccination outweigh concerns over neurological adverse events. BNT162b2, only 17 patients had neurological disorders deemed serious 13 . To address safety concerns of serious neurological AEFI, we extended our ongoing study 14 , of COVID-19-associated neurological disorders in Singapore public hospitals, to describe neurological disorders that occur in patients recently vaccinated with mRNA vaccines. We performed a multi-centre prospective observational cohort study of patients in 7 Singapore public acute hospitals ( Figure 1 ). We included all sequential hospitalized patients who were referred for neurological complaints and had received at least 1 dose of BNT162b2 or mRNA-1273 vaccines in the last 42 days. We examined a hospital-based cohort to focus on serious neurological AEFI as defined by World Health Organization (WHO) 7 . Immediate and short term AEFIs are conventionally studied over 42 days 15 . The study covered 30 December 2020 to 20 April 2021, when selected high risk population groups (healthcare and frontline workers and elderly individuals) were vaccinated 3 . To contextualize our findings, data from the National Immunization Registry was probed for the total number of vaccinated individuals in the corresponding period. The protocol was approved by the Institutional Review Board (CIRB 2020/2410). 1. Patients were evaluated at the discretion of the managing neurologist and relevant clinical, radiological and laboratory data collated. Interval between last vaccine dose and symptom onset (latency) was calculated. was to delay vaccination by 6 months post-COVID-19 infection. Four hundred and thirty-eight patients (95.8%) received BNT162b2 and 19(4.2%) had the mRNA-1273 vaccine. Two hundred and seventyfive (60.2%) cases occurred after the first dose. Seventy-three (16.0%) were grouped into CNS syndromes, 286 (62.6%) cerebrovascular disorders, 59 (12.9%) PNS disorders, none (0%) ANS disorders and 39 (8.5%) ISRR. Median latency was 9(0-40) days. Table 1 summarizes the key neurological disorders and their temporal relationship to vaccines. , spondylotic and ischemic myelopathies (n = 2), acute psychosis (n = 1), central retinal artery occlusion (n = 1), cranial nerve V mononeuropathy (n = 4), vestibular neuronitis (n=1), non-spondylotic radiculopathy (n = 3), spondylotic radiculopathy (n = 5), chronic inflammatory demyelinating polyneuropathy (n = 1), diabetic polyneuropathy (n = 1), myasthenia gravis (n = 2), myopathies (n = 2) and other peripheral vestibulopathies (n = 16). Two (0.4%) patients had extensive CVT (60 and 62 years, both females), 9 and 8 days after second dose respectively. Evaluation for prothrombotic factors (Appendix Table A .3) and malignancy for patient 1 was unremarkable. Despite decompressive hemicraniotomy and anticoagulation with heparin followed by warfarin, she remained neurologically debilitated (mRS 5) 6 weeks later. Patient 2 had a family history of thrombosis (her son had unprovoked pulmonary embolism). Her prothrombotic evaluation (Appendix Table A .3) showed low antithrombin III levels (55%, normal range: 80-120%), attributed to acute thrombosis. She improved with anticoagulation, heparin then warfarin, and recovered to mRS 2 upon discharge. None had thrombocytopenia. Anti-Platelet Factor 4 antibodies were not tested in both patients. We managed 59 ( patients had single neurological symptom: sensory complaints (n = 9), dizziness (n = 2), headache (n = 2), focal twitching (n = 2), and forgetfulness (n = 1); 23 (59.0%) were polysymptomatic: sensory (n = 17), motor (10 weakness and 2 cramps), headache (n = 7), giddiness (n = 5), unsteadiness (n = 3), abnormal movement/twitching (n = 2), dysarthria (n = 2), and visual blurring (n = 2). All except one patient improved prior to discharge. Our hospital-based study covered a 4-month period during which 1,398,074 people received at We then categorized the likelihood of vaccination or a concurrent and coincidental illness explaining the disorder using the WHO AEFI causality assessment, Brighton criteria framework 19 ; Appendix Table A .4). Vaccines can trigger seizures, typically within 24h for inactivated vaccines and 5-12 days after live-attenuated vaccines 15, 20 . The risk period is unknown for novel mRNA vaccines and no cases have person-month 21 , and could be categorised at best, "probable" vaccine-related. Another 18 patients who had seizures within the first 2 weeks but had an alternative explanation, such as poorly controlled epilepsy, were categorized only as "possible". The seizures in the remaining 11 patients were deemed as "unlikely" or "unrelated" as they occurred more than 2 weeks after vaccination and had an alternative explanation. The described risk period for meningoencephalitis after vaccination is 21 days 15 with encephalopathy, who developed illness outside the risk period and had alternative etiologies (CSF leak and hyperglycaemia), were labelled "unlikely" or "unrelated". Dysimmune processes tend to occur 5-28 days after inactivated vaccines; with additional days added for the incubation period of live attenuated vaccines 18 . One case of new-onset MS 7 days after first dose of BNT162b2 was reported 22 . However, an observational study of MS patients who received the BNT162b2 vaccine, showed relapse rates (2.1% and 1.6% after first and second dose respectively) which were similar to non-vaccinated patients 23 . Therefore, we categorized the mild MS flares in 2 patients within this time-frame as only "possible" vaccine-related. The association between vaccination and optic neuritis is less clear 24 . However, the AQP-4 antibody positive optic neuritis that occurred only 1 day after BNT162b2 first dose and the idiopathic optic neuritis that developed 33 days after BNT162b2 second dose, were likely coincidental and classified as "unlikely". Likewise, the other cases recorded in the CNS group. were deemed as "unlikely" or "unrelated". Common disorders such as stroke may occur coincidentally after vaccination. No relationship was found in a recent study based on a national database in Scotland that recorded 0.82 million people who received BNT162b2 25 . The 246 AIS cases out of 1,398,074 vaccinated persons we observed over 4 months lies within the expected local baseline incidence of 16.6 per 100,000 person-month 26 . The median age (70 vs 69 years) and stroke subtypes of our imaging-proven AIS patients were similar to that reported previously, including the Singapore Stroke Registry [26] [27] . Nevertheless, to address concerns of possible links to mRNA vaccines, we analysed patients who were deemed least likely to develop AIS (age  50 years), although this would not account for potential interaction between age and vaccination. No pattern with regards to stroke etiology is discerned; nine of 11 patients had at least 2 cardiovascular risk factors (Appendix Table A .1). They also did not have signs of dysimmunity, prothrombotic state or thrombocytopenia. We did not find clustering of latency in this group, compared to other AIS patients. Overall, the AIS/TIA cases could be explained by pre-existing cardiovascular risk factors and likely occurred independent of the vaccine. We also did not observe any resemblance to VITT; neither did we find any specific stroke pattern nor clustering of latency (6 vs 9 days, p = 0.29) in those with thrombocytopenia (Appendix Table A .2). Majority of CVTs reported post-vaccination have occurred following the adenovirus vector vaccines [28] [29] . Recent reports of possible association between mRNA vaccine and CVT [30] [31] , have been balanced by reassuring data from the Scotland national database 25 . Our 2 CVT cases, 1 idiopathic, the other with family history, could be categorized as "probable" and "possible" vaccine-related respectively. Similar to AIS 32 , the challenge to discerning a causal link between CVT and mRNA vaccine is the uncertainty of the risk period. We recorded 11 cases of Bell's palsy. It is still unclear if the incidence after mRNA vaccines is above the background rate or disproportionate to that of other viral vaccines 2,33-36 . One report estimated an incidence of 106 per 100,000 person-years, against the background rate of 15-30 per 100,000 personyears 36 . The EudraVigilance data suggests a greater than 3-fold increase in Bell's palsy with mRNA vaccines compared to other vaccines 36 . In Singapore, Bell's palsy incidence after mRNA vaccination is and VI (n = 32), occurring largely in isolation at median 9 days. No clustering according to age group or vaccine types was observed 38 . There was one report of a patient who developed CN VI palsy 2 days after BNT162b2 39 . Although our patients developed cranial III and VI neuropathies at median 8 (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) days post vaccination, the link to vaccination is uncertain as these patients also had risk factors for microvascular ischemia. These cases would therefore fall into "possible" category. The low occurrence of GBS (n = 2) is perhaps surprising given the slightly elevated risk of GBS after influenza vaccine 40 . The national incidence of GBS has not increased since vaccination started compared to a baseline of 9 GBS cases per month pre-COVID (personal communications). We recorded 1 patient with new-onset MG, similar to a recent report of 2 patients who developed MG 1 and 7 days after BNT162b2 second dose 22 . Our 3 patients who had exacerbation of MG, CIDP and myositis (2 already had frequent relapses), together with the 2 MS cases, suggest that mRNA vaccines may only occasionally contribute to flares of immune-mediated disease. We recorded 39 patients (8.5%) with ISRR, of whom only a small proportion had previous FND or psychiatric illness. Consistent with previous reports 17, 41 , these patients were younger, a slightly higher proportion were female and majority were polysymptomatic with sensory symptoms being the commonest complaint. There were no clusters of ISRR. WHO had suggested vigilance for potential vaccine-enhanced disease, an AEFI following some live-attenuated vaccines. This refers to a potential increased risk of COVID-19 like disease or its complications. At present, there is no evidence that either of these risks exist for COVID-19 vaccines 7 . We categorized the patients similar to that used to describe COVID-19 neurological complications to facilitate detecting such AEFI. In the Singapore COVID-19 neurology cohort and a subsequent nationwide study 14, 42 , we did not see a significant association of GBS with COVID-19. Likewise, we only recorded 2 patients with GBS after vaccination. Conversely, Bell's palsy predominated the PNS casemix in both cohorts (11 of 59 PNS disorders post-vaccination, and 5 of 7 post-COVID-19 PNS complications) 14 . While CVT is a significant complication of COVID-19 14, 43 , whether this condition is related to COVID-19 mRNA vaccine remains unclear 32 . AIS is associated with COVID-19, often in young patients without cardiovascular risk factors but with signs of dysimmunity and prothrombotic tendency 14, 44 ; while AIS in post-vaccine cohort is likely coincidental. We encountered 4 cases each of localized dysautonomia 45 and severe encephalitis 14,46 associated with COVID-19 but none after vaccination. Our study has several limitations. Investigations were performed at the discretion of the managing neurologist. We did not test for COVID-19 in all patients. None had COVID-19 symptoms or previous COVID-19 and local transmission was less than 5 community cases per day then. As our study was based in public acute hospitals, we would have missed patients consulting outpatient clinics, private hospitals and non-neurologists. The greater number of Bell's palsy, 25 recorded by Singapore's drug regulatory authority, Health Sciences Authority (HSA), versus 11 in our study, during the same period illustrates this point 37 . The first 4 months of the vaccine drive was focused on frontline workers and elderly patients (Appendix Figure A. 2); hence our study findings may not be generalizable to the general population. A large number of individuals were vaccinated over a short period of time, engendering overestimation of normally infrequent AEFI 35 . Our study findings therefore do not reflect that of a steady-state vaccination programme. In addition, not all the background incidence rates of the disorders described were available. Data from a control group comprising unvaccinated patients hospitalized in J o u r n a l P r e -p r o o f the same period was also unavailable. The published risk periods that guided us might be inapplicable to novel vaccines and regimens (2 doses over a few weeks). The discussion on biological plausibility, although guided by contemporaneous literature, is also inevitably quite arbitrary. The cases we described in our observational study, which cannot establish causality to vaccination, could have been purely coincidental and occurred independent of the vaccine. Despite these limitations, we present systematically collected data in a multi-centre study and contextualised them against the total number of vaccinated individuals, instead of reporting individual cases with uncertain link to vaccine, in order to identify possible signals of serious AEFIs. Over a J o u r n a l P r e -p r o o f Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Efficacy and safety of the mRNA-1273 SARS-CoV-2 Vaccine Ministry of Health Government accepts recommendations of expert committee on COVID-19 vaccination Ministry of Health COVID-19 vaccines: ethical framework concerning human challenge studies Challenges and scientific prospects of the newest generation of mRNA-based vaccines against SARS-CoV-2 Vaccine-and natural infection-induced mechanisms that could modulate vaccine safety World Health Organization. Covid-19 vaccines: safety surveillance manual -monitoring and responding to adverse events following immunization World Health Organization Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination ANA investigates: neurological complications of COVID -19 vaccines Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study Safety of COVID-19 vaccines administered in the EU: Should we be concerned? Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study Neurology of COVID-19 in Singapore Near real-time surveillance for influenza vaccine safety: proof-of-concept in the vaccine safety datalink project The how's and what's of vaccine reactogenicity. NPJ Vaccines World Health Organization. Immunization stress-related response: a manual for program managers and health professionals to prevent, identify and respond to stress-related responses following immunization World Health Organization SO2-D2.5.2.1 -AESI case definition companion guide for 1st tier AESI anaphylaxis Coalition for Epidemic Preparedness Innovations Revised World Health Organization (WHO)'s causality assessment of adverse events following immunization-a critique Vaccination triggers, rather than causes, seizures. Epilepsy Curr First seizure definitions and worldwide incidence and mortality Immune-mediated disease flares or new-onset disease in 27 subjects following mrna/dna sars-cov-2 vaccination. Vaccines COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by Ocular adverse events following vaccination: overview and update First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland Singapore stroke registry annual report National Registry of Diseases Office Embolic strokes of undetermined source: the case for a new clinical construct. The Lancet Neurology US Case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination Ischaemic stroke as a presenting feature of ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia Cerebral venous thrombosis after BNT162b2 mRNA SARS-CoV-2 vaccine Cerebral venous thrombosis and portal vein thrombosis: a retrospective cohort study of 537,913 COVID-19 cases. medRxiv Vaccination against COVID-19: insight from arterial and venous thrombosis occurrence using data from VigiBase US authorization of first COVID vaccine marks new phase in safety monitoring Association of facial paralysis with mRNA COVID-19 vaccines: a disproportionality analysis using the world health organization pharmacovigilance J o u r n a l P r e -p r o o f Journal Pre-proof database Bell's palsy and SARS-CoV-2 vaccines Bell's palsy and SARS-CoV-2 vaccines-an unfolding storyauthors' reply HSA's safety update #1 Pfizer-BioNTech and Moderna COVID-19 vaccines Health Sciences Authority Motor palsies of cranial nerves (excluding VII) after vaccination reports to the US vaccine adverse event reporting system Acute abducens nerve palsy following COVID-19 vaccination Investigation of the temporal association of guillain-barre syndrome with influenza vaccine and influenzalike illness using the United Kingdom general practice research database Anxiety-related adverse events following immunization (AEFI): a systematic review of published clusters of illness. Vaccine Guillain-Barré syndrome decreases in Singapore during the COVID-19 pandemic Cerebral venous thrombosis in patients with COVID-19 infection: a case series and systematic review Acute ischemic stroke during the convalescent phase of asymptomatic COVID-2019 infection in men Acute hyperhidrosis and postural tachycardia in a COVID-19 patient Encephalopathy in COVID-19 patients; viral, parainfectious, or both? eNeurologicalSci Clinical event with a plausible time to vaccine administration, and which cannot be explained by concurrent disease or other drugs. Clinical event with a reasonable time relationship to vaccine administration, and is unlikely to be attributed to concurrent disease or other drugs. Clinical event with a reasonable time relationship to vaccine administration, but which could also be explained by concurrent disease or other drugs. Clinical event whose time relationship to vaccine administration makes a causal connection improbable, but which could plausibly be explained by underlying disease or other drugs. Clinical event with an incompatible time relationship to vaccine administration and which could be explained by underlying disease or other drugs. 1. Puliyel J, Naik P. Revised World Health Organization (WHO)'s causality assessment of adverse events following immunization-a critique. F1000Res. 2018 Feb 28;7:243.